Appendix Table C6. KQ1: Darbepoetin versus epoetin, study quality

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **study author** | **random** | **allocation** | **blinding** | **placebo** | **ITT or 10%** | **similar****baseline characteristics** | **high or low quality** | **publication** |
| **Glaspy 2002, Part A** | unclear | unclear | no | no placebo | ITT or 10% | yes | low | full text |
| **Glaspy 2006** | unclear | yes | no | no placebo | ITT or 10%, not for QoL | yes | low | full text |
| **Schwartzberg 2004** | unclear | unclear | no | no placebo | ITT or 10% | yes | low | full text |
| **Waltzman 2005** | unclear | unclear | no | no placebo | ITT or 10%, more pts excluded for QoL | yes | low | full text |
| **Kotsori 2006** | unclear | NR | NR | no placebo | NR | NR | low | abstract |